Transforming metastatic cancer from a terminal prognosis to a manageable disease
Valuation cap ⓘ
$25.0M
As of Jan 2022 · from Lifebridge 10000, LLC Future Equity SAFE 2 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$189,769
Across 3 rounds since 2017
Latest share price
$1.04
Reg CF Offering (2025) offering price
Financials
FY2015–FY2024 · from SEC filings · hover any figure for its source
$0
−$44K
2017
$0
−$125K
2018
$0
−$339K
2019
$43K
−$324K
2020
$0
−$478K
2021
$0
−$855K
2022
$0
−$980K
2023
$0
−$1.8M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Chart shows the most recent 8 fiscal years; 2 earlier years are in the table below.
Metric
FY2015
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
Income statement
Revenue
$0
$0
$0
$0
$0
$42,650
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Gross margin
—
—
—
—
—
100%
—
—
—
—
Net income
-$26,520
-$161,855
-$44,491
-$124,595
-$338,897
-$324,145
-$478,000
-$855,000
-$979,838
-$1,756,241
Taxes paid
$0
$0
$0
$0
$0
$5,550
$0
$0
$0
$0
Balance sheet
Cash
$989
$404
$5,895
$49,991
$10,885
$164,023
$79,000
$412,000
$1,205,266
$625,569
Accounts receivable
$0
$0
$0
$0
$0
$0
$0
$0
$1,350
$880
Total assets
$989
$23,016
$28,247
$72,159
$34,402
$177,484
$103,000
$984,000
$1,226,262
$819,888
Short-term debt
$0
$9,840
$10,875
$10,340
$6,457
$6,357
$3,200
$162,000
$46,272
$123,013
Long-term debt
$0
$0
$0
$0
$0
$0
$171,000
$516,000
$516,578
$523,704
Total liabilities
$0
$9,840
$10,875
$10,340
$6,457
$6,357
$174,200
$678,000
$562,850
$646,717
Other
Headcount
—
4
4
4
4
4
—
4
—
3
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.